Allergan (AGN) Strong With or Without DARPin - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Lazard Capital Upgrades Allergen (AGN) to Buy
May 2, 2013 7:11 AM EDTLazard Capital upgraded Allergen (NYSE: AGN) from Hold to Buy.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $98.67 yesterday, with a 52 week range of $81.28-$116.45.... More
Morgan Stanley Downgrades Allergen (AGN) to Equalweight
May 1, 2013 2:31 PM EDTMorgan Stanley downgraded Allergen (NYSE: AGN) from Overweight to Equalweight.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $113.55 yesterday, with a 52 week range of $81.28-$116.45.... More
Allergan (AGN) Says DARPin to Be Delayed, Shares Sag; Regeneron (REGN) Ramps Higher
May 1, 2013 11:26 AM EDTAllergan Inc. (NYSE: AGN) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) traded in opposite directions mid-day Wednesday after Allergan's CEO David Pyott said data on DARPin does not support Phase 3 trials, which will delay approval by 1-2... More
Regeneron (REGN) Share Spike, Volatility Halt Appears Related to Allergan News
May 1, 2013 11:13 AM EDTUPDATE: The spike and subsequent circuit breaker trading halt in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) appears related to news from Allergan, Inc. (NYSE: AGN) that Darpin data does not support Phase 3 trials.... More
Allergan (AGN) says Darpin data does not support Phase 3 trials.
May 1, 2013 11:08 AM EDTUPDATE: Allergan, Inc. (NYSE: AGN) says Darpin data does not support Phase 3 trials. (halted on breaker)... More
Allergan, Inc. (AGN) trading paused for volatility
May 1, 2013 11:06 AM EDTAllergan, Inc. (NYSE: AGN) trading paused for volatility.... More
